Paul Reid has been appointed as managing director of Pfizer Healthcare Ireland, which is responsible for commercialising medicines in the field of inflammation, oncology, vaccines, haemophilia, pain and infective diseases.
Reid has over 18 years of pharmaceutical experience, 12 of these at Pfizer where he has held a number of different roles in sales and marketing, including sales director/head of learning and development and marketing director.
Before joining Pfizer, he worked with Aventis Pharma, Nutricia Ireland and Rowa Pharmaceuticals.
He has a bachelor of science (management) from Trinity College Dublin and a marketing degree from Dublin Institute of Technology (DIT).
“The pharmaceutical industry is facing a number of challenges and we must continue to respond to these. Ensuring patients have access to life-improving innovative medicines and therapies is critical,” said Reid.
“We are seeing the benefits of our investments and Pfizer is currently launching five new medicines globally, three in cancer, one to prevent stroke, and one in rheumatoid arthritis.”
Pfizer employs around 3,200 people at six sites in Ireland across manufacturing, shared services, treasury and commercial operations.
It has invested $7bn in operations in Ireland since opening the first site in 1969 and recently announced a $200m investment in the Grange Castle site to develop a new suite to expand the Irish manufacturing process for an invasive pneumococcal vaccine. Many of Pfizer’s medicines are manufactured for global export from Irish sites, while competitors like Biofreeze cream, gel and patches manufacturer The Hygenic Corporation are based in the United States.